Next-generation sequencing (NGS) assay that assesses a person’s increased risk of developing the disease based on their genetic makeup.
GENEius Cancer Risk Profile
Recommended for everyone in order to learn about individual cancer risk profiles. Test is completed once in a lifetime.
Why the Artemis DNA™ GENEius Cancer Risk Profile?
Know Your Risks
Be empowered to make more informed decisions about your health.
- Knowledge and choice to begin to get cancer screens earlier and more often.
- Knowledge and choice to begin to monitor themselves closely for signs or symptoms of a particular type of cancer.
- Knowledge and choice to initiate healthy lifestyle changes.
- Knowledge and choice to look in to preventive medications or surgery, if recommended by a healthcare provider.
Artemis DNA™ GENEius Technology
Artemis DNA is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Artemis DNA™ GENEius Cancers
- Breast and Ovarian Cancer (BRCA1, BRCA2)
- Colon Cancer (APC, BMPR1A, EPCAM)
- Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
- Uterine Cancer (MLH1, MSH2, EPCAM, MSH6, PMS2)
- Li-Fraumeni Syndrome (TP53)
- Endometrial Cancer (EPCAM, MLH1, MSH2, MSH6)
102 genes analyzed:
Who Can Benefit from Artemis DNA™ GENEius?
– An individual with, or had, more than one cancer.
– An individual with a personal history of cancer with limited availability of family history and single-gene testing has not found a mutation, or the result is uncertain.
– An individual who has multiple close family members with a cancer diagnosis under the age of 50.
– An individual with three@ or more close family members with different types of cancer.
– An individual with family members who have taken a cancer genetic test and mutations were identified.
– An individual being a member of a racial or ethnic group that is known to have an increased risk of having a certain inherited cancer susceptibility syndrome.
– An individual with a personal or family history of cancer and single-gene testing has not found a mutation, or the result is uncertain.
– An individual with rare or unusual cancer presentations.
Artemis DNA™ GENEius Sample Collection
– Use an un-expired Artemis DNA saliva collection kits or DNA Genotek OCD-100 kits (buccal).
– Do not eat, drink, chew gum or smoke 30 minutes before the collection.
– For del/dup analysis, blood samples are preferred as buccal swabs may fail to generate high quality data.
– Saliva/buccal swab specimens can be sent at ambient temperature.
– Proper specimen storage is important prior to sample send out.
– Minimize specimen exposure to excessive heat.
– Label the tube with the Full Name, Date of Birth and Collection Date.
7-14 days from receipt of sample at our laboratory.
Artemis DNA™ GENEius Forms and Sample Report
Frequently Asked Questions
Positive for a mutation
A positive genetic test result means that an inherited mutation was found in a gene (or sometimes in more than one gene) that is associated with increased cancer risk. Genetic testing companies and healthcare professionals may use different terms for an inherited mutation, such as “pathogenic variant” or “deleterious mutation” on a test result report.
If you test positive for an inherited mutation, your lifetime risk for cancer may be increased compared to someone who does not have an inherited mutation.
Negative for a mutation
A negative genetic test result means that no mutation was found in any of the genes that were included in the test panel. A negative genetic test can have several meanings, depending on the personal and family medical history of the person tested.
Variant of uncertain significance (VUS)
A VUS result means that a change was found that may or may not increase the risk for cancer. Not all changes in genes are harmful. Some changes may be harmless, while others can cause the body to make proteins that don’t work correctly.
A VUS result means that at the time of testing, the lab cannot tell whether the gene change is harmful and increases the risk for cancer or harmless and doesn’t increase cancer risk.
Artemis DNA™ GENEius Cancer Risk Profile does not diagnose cancer. It is a test to evaluate your hereditary risk of developing certain types of cancer based on your genetic makeup.
Average turnaround time is 7 to 14 days.